Pancreatic Cancer Research

ResearcherStanford MedicineActive in the last 2 years

George Albert Fisher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6828-3938; OpenAlex author ID A5036188351. Sources: ClinicalTrials.gov.

Their work

Papers
25 (first author 0, last author 1)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
119
Papers, trials and grants by year

2004: 1 trial · 2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: 1 trial · 2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 25

  1. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Co-author DOI 10.1097/sla.0000000000006609↗
  2. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  3. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  4. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  5. Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Co-author DOI 10.1245/s10434-023-13120-3↗
  6. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
  7. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
  8. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  9. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Co-author DOI 10.2217/imt-2021-0008↗
  10. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalatio… Co-author DOI 10.1016/s2468-1253(20)30088-1↗
  11. Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer. Last author DOI 10.1089/pancan.2020.0015↗
  12. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  13. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  14. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.11.008↗
  15. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Co-author DOI 10.1097/mpa.0000000000001314↗
  16. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  17. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Co-author DOI 10.1097/mpa.0000000000001133↗
  18. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Co-author DOI 10.1245/s10434-018-6453-2↗
  19. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cance… Co-author DOI 10.1016/j.prro.2016.05.005↗
  20. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Co-author DOI 10.1002/cncr.29161↗
  21. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… Co-author DOI 10.1186/2051-1426-3-s2-p155↗
  22. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Co-author DOI 10.1016/j.ijrobp.2014.06.066↗
  23. Symptoms and palliative care needs of pancreatic adenocarcinoma patients. Co-author DOI 10.1089/jpm.2014.0056↗
  24. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2011.09.035↗
  25. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2010.05.006↗

Trials 3

  1. A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma Principal investigator NCT01108458↗
  2. Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Principal investigator NCT00547144↗
  3. Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer Principal investigator NCT00185588↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George A. Poultsides · 10 shared papers, 2012–2026 · strength 1.02
  2. Andrew H. Ko · 8 shared papers, 2015–2026 · strength 0.90
  3. Daniel Tandel Chang · 10 shared papers, 2011–2026 · strength 0.88
  4. Eileen Mary O'Reilly · 8 shared papers, 2015–2026 · strength 0.77
  5. Robert H. Vonderheide · 6 shared papers, 2015–2026 · strength 0.67
  6. Robert A. Wolff · 5 shared papers, 2019–2026 · strength 0.60
  7. Brendan Christopher Visser · 5 shared papers, 2012–2026 · strength 0.56
  8. Zev A. Wainberg · 4 shared papers, 2021–2026 · strength 0.54
  9. Mark H. O’Hara · 4 shared papers, 2021–2026 · strength 0.54
  10. Erqi Liu Pollom · 4 shared papers, 2014–2026 · strength 0.54
  11. Lacey Padrón · 3 shared papers, 2022–2026 · strength 0.45
  12. William Arthur Hoos · 3 shared papers, 2021–2026 · strength 0.43
  13. Albert C. Koong · 7 shared papers, 2011–2023 · strength 0.42
  14. Daniel A. King · 3 shared papers, 2020–2023 · strength 0.37
  15. Jeffrey Allen Norton · 4 shared papers, 2011–2026 · strength 0.33
  16. Osama E. Rahma · 3 shared papers, 2021–2024 · strength 0.32
  17. Joseph M. Herman · 4 shared papers, 2015–2023 · strength 0.29
  18. R. Brooke Jeffrey · 2 shared papers, 2019–2023 · strength 0.25
  19. Diego A.S. Toesca · 2 shared papers, 2019–2023 · strength 0.25
  20. Eben Lloyd Rosenthal · 3 shared papers, 2018–2020 · strength 0.24
  21. M. Usman Ahmad · 1 shared paper, 2026 · strength 0.24
  22. Byrne Lee · 1 shared paper, 2026 · strength 0.24
  23. Gregory M. Heestand · 1 shared paper, 2026 · strength 0.24
  24. Daniel Delitto · 1 shared paper, 2026 · strength 0.24
  25. Amanda Kirane · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.